Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yun Fan

Showing results (841-850 of 920) with videos related to

Pageof 92
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 5, 2025
Quantitative and Dynamic ctDNA as a Biomarker of Response and Survival in Patients With Advanced Lung Squamous Cell Carcinoma Receiving Immunochemotherapy or Chemotherapy AloneFei Zhou, Jiao Zhang, Shengxiang Ren, et al.
Cancer Immunology, Immunotherapy : CII|October 20, 2021
Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II studyJin-Ji Yang, Cheng Huang, Yun Fan, et al.
The Lancet. Respiratory Medicine|June 24, 2021
Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 studyShun Lu, Jian Fang, Xingya Li, et al.
JTO Clinical and Research Reports|June 6, 2022
Long-Term Efficacy and Safety of Entrectinib in <i>ROS1</i> Fusion-Positive NSCLCAlexander Drilon, Chao-Hua Chiu, Yun Fan, et al.
Gastroenterology|November 26, 2008
2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis BYun-Fan Liaw, Edward Gane, Nancy Leung, et al.
Chemistry & Biodiversity|December 19, 2025
Anticancer, Anti-Inflammatory, and Acute Toxicological Evaluation of the Novel Berberine Derivative BN-7Ren-Tao Zhang, Qi-Qi Xie, Xiao-Long Sun, et al.
JAMA Oncology|September 2, 2021
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical TrialLeora Horn, Ziping Wang, Gang Wu, et al.
Signal Transduction and Targeted Therapy|October 15, 2021
Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trialTao Jiang, Pingyang Wang, Jie Zhang, et al.
Lung Cancer (Amsterdam, Netherlands)|January 15, 2024
Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES)Ying Cheng, Lin Wu, Dingzhi Huang, et al.
Cell Research|June 23, 2010
Complete genome sequence of the rifamycin SV-producing Amycolatopsis mediterranei U32 revealed its genetic characteristics in phylogeny and metabolismWei Zhao, Yi Zhong, Hua Yuan, et al.
Pageof 92

Showing results (841-850 of 920) with videos related to

Sort By:
Pageof 92
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 5, 2025
Quantitative and Dynamic ctDNA as a Biomarker of Response and Survival in Patients With Advanced Lung Squamous Cell Carcinoma Receiving Immunochemotherapy or Chemotherapy AloneFei Zhou, Jiao Zhang, Shengxiang Ren, et al.
Cancer Immunology, Immunotherapy : CII|October 20, 2021
Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II studyJin-Ji Yang, Cheng Huang, Yun Fan, et al.
The Lancet. Respiratory Medicine|June 24, 2021
Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 studyShun Lu, Jian Fang, Xingya Li, et al.
JTO Clinical and Research Reports|June 6, 2022
Long-Term Efficacy and Safety of Entrectinib in <i>ROS1</i> Fusion-Positive NSCLCAlexander Drilon, Chao-Hua Chiu, Yun Fan, et al.
Gastroenterology|November 26, 2008
2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis BYun-Fan Liaw, Edward Gane, Nancy Leung, et al.
Chemistry & Biodiversity|December 19, 2025
Anticancer, Anti-Inflammatory, and Acute Toxicological Evaluation of the Novel Berberine Derivative BN-7Ren-Tao Zhang, Qi-Qi Xie, Xiao-Long Sun, et al.
JAMA Oncology|September 2, 2021
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical TrialLeora Horn, Ziping Wang, Gang Wu, et al.
Signal Transduction and Targeted Therapy|October 15, 2021
Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trialTao Jiang, Pingyang Wang, Jie Zhang, et al.
Lung Cancer (Amsterdam, Netherlands)|January 15, 2024
Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES)Ying Cheng, Lin Wu, Dingzhi Huang, et al.
Cell Research|June 23, 2010
Complete genome sequence of the rifamycin SV-producing Amycolatopsis mediterranei U32 revealed its genetic characteristics in phylogeny and metabolismWei Zhao, Yi Zhong, Hua Yuan, et al.
Pageof 92